U.S. Medical Equipment Stock News

Geron stock jumped 21.6% to US$1.63 on the first trading day after its Q2 release, a sharp move for a company long viewed as a discounted oncology developer with a long road to profitability. The headline is simple: solid revenue traction from RYTELO and stable operating spend have pulled losses into a narrower band, while the balance sheet still carries US$327m of cash. For a stock that came into earnings with modest double digit gains over 1, 3 and 6 months, this report has turned what was...

SpaceX has just shocked the market by pouring $18.4b into AI projects, with spending far beyond its recent revenue jump and sending the stock sharply lower. That kind of aggressive move can reshuffle where capital flows across the wider AI infrastructure space. This article walks through 3 stocks exposed to this news, explaining how they might be affected by the surge in cloud and compute demand and outlining where key risks could sit. The stocks covered below are just a starting sample from...

CorVel’s stock jumped 5.9% to US$62.57 into the close, which indicates traders responded positively to the results. The key point is that the earnings beat was meaningful. Revenue reached about US$259.9m and basic earnings per share came in near US$0.63, with the quarter supported by strong performance in payment integrity and broader workers’ compensation services. CorVel entered this report with mixed short-term returns but a solid earnings track record and a valuation that already sat...

Hudson Pacific Properties stock jumped 7.1% to US$14.97 after the Q2 release, a sharp move for a company that came into today with a flat week and a tough recent track record. The headline was not earnings per share. The market latched on to a different story. Core funds from operations, or core FFO, nearly tripled to US$23.1 million and management nudged full year core FFO guidance higher. The short term price pop is about relief and renewed confidence. The bigger question for you is whether...

Ultragenyx Pharmaceutical stock slipped 3.4% to about US$24.93 as investors digested a fresh set of numbers that mixed record sales with continued losses. Q2 revenue reached US$214m, led by rare disease drugs such as Crysvita, while the company still reported a net loss of US$92m, or US$0.90 per share. For traders focused on this week, that loss keeps the pressure on. For investors thinking in years rather than days, the key points are the record top line, the active late stage pipeline and...

Guardant Health stock has delivered very strong returns over the past few years, yet the signals on what that means for valuation are mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market multiples suggest the shares screen expensive. Guardant Health has returned 347.6% over the past three years, which puts extra focus on whether the current share price leaves much margin for error. Growing adoption of the Guardant360 and Shield blood tests may...

FRP Holdings stock slipped 2.4% to US$21.93 after its Q2 report, yet the real story sits in a different place than the share chart. The headline this quarter is a squeeze on profitability. Trailing net profit margin has compressed to 0.3% compared with 16.5% a year earlier, and reported earnings over the past five years have retreated at an average rate of 45.8% a year. Investors are reacting to that margin picture more than to the solid real estate platform or cash on hand. The question now...

Marqeta stock just handed investors a 7% one day drop, yet the earnings story leans far more toward a profitability grind than a collapse. Coming into the print, the stock had been roughly flat over three months, with only a small gain over 30 days. Then the market met a payments platform that printed about US$176m in Q2 net revenue and roughly US$8m in net income, its second straight profitable quarter. The real headline is margin power. Adjusted earnings before interest, tax, depreciation...

Louisiana-Pacific stock barely budged after earnings, up just 0.7% to US$77.36, yet the quarter itself was anything but quiet. The company posted Q2 2026 revenue of US$664m and basic earnings per share of US$0.37, with investors weighing those construction cycle exposed numbers against a rich trailing P/E of about 100x. The real story for you is the squeeze between modest profits and a high multiple, especially with trailing net profit margin running at 2.2% and a recent one off loss still...

Zeta Global Holdings went into this earnings print as a high growth marketing and AI platform stock with a loyal bull camp and a lot to prove on profitability. The market liked what it saw. The share price jumped 11.6% to US$27.07 after the release, extending a strong three month run. The headline this quarter is profit. Zeta Global Holdings shifted from a loss in Q1 to GAAP net income of US$8.2 million, with basic earnings per share of US$0.03, on revenue of US$442.8 million. That move into...

Healthpeak Properties stock barely budged, up less than 1% to around US$21.79, even though the earnings story was all about stronger cash generation. For a real estate investment trust, funds from operations is what matters, and Healthpeak reported adjusted funds from operations of US$0.46 per share in the quarter with total revenue of US$771.6m. The market reaction looks muted compared with that core cash figure and a raised full year adjusted funds from operations guidance range. Investors...

Banc of California, Inc. reported second-quarter 2026 results showing net interest income of US$250.5 million but a net loss of US$241.35 million, a reversal from net income a year earlier, alongside basic and diluted losses per share of US$1.61 from continuing operations. The quarter also saw net charge-offs surge to US$160,281,000 from US$44,222,000 a year ago, highlighting a sharp deterioration in credit costs even as management emphasized balance sheet repositioning efforts. We’ll now...

Niagen Bioscience stock just absorbed a sharp reality check, closing at US$2.96, which is a 14.7% slide from the prior session. That kind of move grabs attention, yet the Q2 print itself was more muted than the chart suggests. Revenue landed at US$29.8m and net income was about US$1m, keeping the company in the black but at a much slimmer level than earlier quarters. For investors with a longer lens, the headline is not the single quarter. It is how this thinner profitability sits against...

The market just put Gibraltar Industries on a pedestal. The stock jumped 14.2% to US$54.86 the first trading day after earnings, after already strong gains over the past quarter. That kind of one day repricing only happens when investors decide the story has changed. The headline this time is clear. Q2 revenue reached about US$509.5m with the first full quarter of OmniMax in the fold and adjusted earnings per share landed solidly in profitable territory after a weak Q1. The real question for...

Sally Beauty Holdings reported past third-quarter 2026 results showing sales of US$935.49 million and higher year-on-year earnings, while also trimming its full-year Fiscal 2026 consolidated net sales guidance to a range of US$3.73 billion to US$3.73 billion. At the same time, the company is pushing COLORfest and COLORfest on Campus and broadening into skin and body care, highlighting a focus on younger consumers and higher-margin categories despite its more cautious sales outlook. We’ll now...

Merger terms reshape the outlook for Supernus Pharmaceuticals stock Supernus Pharmaceuticals (SUPN) is in focus after Indivior Pharmaceuticals agreed on a US$3.6b all stock merger of equals, with Supernus investors set to receive Indivior shares based on a fixed exchange ratio. See our latest analysis for Supernus Pharmaceuticals. The merger announcement comes as Supernus Pharmaceuticals’ share price has moved sharply on the day with an 8.46% 1 day share price return, yet its year to date...

Global Payments slipped 0.9% to close at US$87.48 on Thursday, a muted reaction for a stock that had climbed roughly 25% over the past three months. The headline from this earnings release is not the top line. It is the pressure running through the income statement and into the valuation. Trailing net profit margins sit at 4.8% and interest expense is not well covered by earnings, yet the stock trades on a P/E of 47.1x against much lower peer and industry multiples. For short term traders...

McDonald's stock added 2.1% today, a calm move for a company that just posted one of its more emotionally charged quarters in years. The market appears to be latching onto a clean headline: basic earnings per share came in at US$3.32 and global same restaurant sales grew 1.3%. The real story is a profit engine that still throws off cash while U.S. execution missteps stir anxiety. For now, investors are treating this as a fixable margin and traffic wobble rather than a broken profit model. The...

Ramaco Resources stock came into today already on the back foot after a 30 day slide of about 24%, and the earnings release did little to cheer traders. The share price dropped another 4.2% to US$9.24 as the market focused on another quarterly loss and continued to treat the stock as a high risk story. The headline is simple. Ramaco Resources is still losing money on its coal business, with Q2 basic earnings per share in the red and net income showing a double digit million loss, even as...

NNN REIT stock barely flinched after earnings, edging up about 0.4% to US$47.36. That muted move sits awkwardly against a quarter built around one clear headline: the real story is cash generation. Adjusted funds from operations, or AFFO, reached US$0.90 per share and supported a quarterly dividend of US$0.62 with room to spare. For a net lease REIT that lives or dies on rent checks and payout capacity, the raised full year AFFO guidance and tighter bad debt outlook matter far more than...

Prudential Financial stock slipped about 2.7% to US$120.16 into the close, even as the earnings story pointed in the opposite emotional direction. The headline was profitability, not price. After tax adjusted operating income reached US$1.4b, or US$4.08 per share, and year to date adjusted operating return on average equity reached 15.5%. For a large insurer that balance between earnings power and capital efficiency is what matters. Today’s selling looks more like a knee jerk reaction than a...

trivago stock slipped 2.5% to €5.18 heading into the close, even though the headline from Q2 is simple. Revenue reached €168.4m and the company stayed profitable on a trailing twelve month basis with earnings from continuing operations of €13.1m. The near term read is mixed for traders who focused on the quarterly loss. The longer term picture is more about a business that has swung into profit over the past year while the stock still sits well below one discounted cash flow estimate. That...

Bioventus stock jumped 13.7% today, and for once the emotional surge has a clear anchor in the numbers. The company just printed a muscular Q2 earnings story for a mid cap medical device player, with adjusted EBITDA of US$35 million on US$153.2 million of revenue and a 23% margin. That is the thread driving sentiment right now. The market is cheering a business that is not only profitable but also converting that into cash, with US$20 million from operations and net leverage near 2x. The...

Extreme Networks went into this earnings print with the stock already under pressure over the past month, and then the market hit it again with a 19% drop to about US$26 in the first session after results. That move suggests investors were braced for disappointment. The headline, however, is a different story. Quarterly revenue reached about US$339 million and non GAAP earnings per share came in at US$0.32, while management backed that up with guidance that points to product growth and higher...